1Fisher MD,D' Orazio A.Phase Ⅱ and Ⅲ trials:comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594)[J].Clin Lung Cancer,2000,2(1):21-22.
3Leighl NB,Shepherd FA,Kwong R,et al.Goodwin PJ.Economic analysis of the TAX 317 trial:docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer[J].J Clin Oncol,2002,20(5):1344-1352.
4Hanna N,Shepherd FA,Fossella FV,et al.Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597.
5Albain KS,Rusch VW,Crowley JJ,et al.Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages ⅢA(N2) and ⅢB non-small-cell lung cancer:mature results of Southwest Oncology Group phase Ⅱ study 8805[J].J Clin Oncol,1995,13(8):1880-1892.
6Gandara DR,Chansky K,Albain KS,et al.Consolidation docetaxel after concurrent chemoradiotherapy in stage ⅢB nonsmall-cell lung cancer:phase Ⅱ Southwest Oncology Group Study S9504[J].J Clin Oncol,2003,21 (10):2004-2010.
7Simon GR,Sharma S,Cantor A,et al.ERCC1 expression is a predictor of survival in resected patients with non-small-cell lung cancer[J].Chest,2005,127 (3):978-983.
8Herbst RS.Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients[J].Semin Oncol,2003,30(1 Suppl 1):30-38.
9Bezjak A,Tu D,Seymour L,et al.Symptom improvement in lung cancer patients treated with erlotinib:quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21[J].J Clin Oncol,2006,24:3831-3837.
10Sandler A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355 (24):2542-2550.
